Member Info for 54retiresoon

I hold both started investing in TRX late 2019 and Avacta early 2020. TRX average is 1.21 (after topping up this morning on news). Avacta average is 59p. I am confident on both but see Avacta as more likely to explode on release of trial data but TRX is looking very good long term as moves into profit. Amazed that share price has not moved up with this RNS - I guess because there are no numbers but looks big news to me. Really pleased with CEO after being stung by quick and dirty heavily discounted placed under previous management.

If it was not activating why would :-
1) Avacta have progressed AVA3996 - needs to be activating
2) Avacta be progressing TMAC which combines Affimers and Precision - needs to be activating
3) Avacta have ODD from FDA - needs to be activating
4) Avacta have secured £55m loan - due diligence needs to be activating

Running late

https://www.findaphd.com/phds/project/mrc-dimen-doctoral-training-partnership-difficult-to-cure-treating-hypoxic-tumours-with-targeted-drug-delivery-using-new-hypoxia-responsive-nanocomposites/?p150646

Looks like GSK need to find better oncology drugs - second poor outcome inside a week from a trial

https://www.londonstockexchange.com/news-article/GSK/gsk-update-zejula-2l-in-us/15711568

https://www.londonstockexchange.com/news-article/GSK/dreamm-3-phase-iii-trial-for-blenrep/15703652

Who you going to call ???? AVACTA

I now think that Avacta will not only keep AVA6000 in-house but also aim to keep all their pipeline of off patents including AVA3996. Their licensing deals will be for applying Precision to big Pharma companies existing patented oncology drugs. Given the limited monies raised for Precision developments in the fund raise I think they have at least two deals inked ready to go on release of Phase 1a readout.

I'm working on that 24000 down 63000 to go but just postpones the LTA charge to 75.

Just a few Reasons why
1. Scarring from LFT
2. We're on AIM not NASDAQ
3. We're British not American
4. They want it in black and white in an RNS

For LTH it's a case of add when you can and don't take too much of your investment off the table too early. Although the Lifetime Allowance could be a bit of a problem for me and others when the market adjusts.

I hold my Avacta shares across 4 different Fidelity accounts - SIPP, Drawdown, ISA and GIA. I am maxed out on my ISA with no cash in either the ISA account or drawdown account and hold only Avacta shares in those two accounts.

Fidelity can transfer the open offer entitlement from the ISA and add it to the GIA entitlement (but presumably this takes them a few days) so if you are in similar position you need to act fast to get them moved.

The open offer entitlement for the Drawdown shares cannot be transferred into either SIPP or GIA so only option is to sell enough shares in open market to buy those in the open offer for, at current price for me, an extra 9 shares.

Banerji described a range of methods for targeting cancer cells and explained how Avacta’s lead pre|CISION drug candidate, AVA6000, currently in a Phase I trial to treat soft tissue sarcoma, is different. According to Banerji, AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using pre|CISION technology. This technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAP), which is upregulated in the tumor microenvironment but is less abundant or absent in healthy cells. Avacta’s doxorubicin FAP targeted drug is designed to selectively release active chemotherapy in the tumor. This reduces exposure to doxorubicin’s cytotoxic effects on healthy cells, while simultaneously increasing its therapeutic effects on cancerous ones.

See comments from Udai Banerji - Institute of Cancer Research at the Open Day

He knows it works

https://www.genengnews.com/topics/cancer/avacta-sets-up-shop-in-west-london/#:~:text=Avacta%20found%20a%20home%20in,out%20Alastair%20Smith%2C%20Avacta's%20CEO

Great deal and boost to turbo charge Diagnostics and Affimers. Could it also be that they have decided to keep AVA3996 in-house or they want to strengthen their hand in negotiations for licensing Precision to Big Pharma.

Your Chief Scientific Officer does not address a FAP Summit about Pre-Clinical Development of your lead drug after 1yr of a Phase 1 data rich trial if it does not work.

https://www.icpo-fap-summit.org/files/ICPO%20FAP%20Summit%202022/downloads/ICPO2022_ICPO_Theranostics_FAP_Summit_Preliminary_Programme.pdf

Look at who is speaking in the first slot on session 6 on Saturday. Fiona McLaughlin on AVA6000

David Wilson - Commercial Director Diagnostics is down as a speaker at Coronavirus Virtual Event on 19th October.

https://www.labroots.com/virtual-event/coronavirus

Is it better for humankind that Avacta remain independent and license out Precision to multiple pharmas to improve their existing drugs or for one of the big pharmas to acquire Avacta and have exclusivity for Precision plus Affimers plus TMAC?

Surely maximum benefit comes from allowing as many as can affford it to press ahead with developing safer oncology drugs.

Happy to add an extra 1000 shares @117 - this was 140p last week before two excellent RNSs.

Conifer cannot hold 3.33% unless bought more in last couple of days as would have required an RNS.
The top three holdings if correct are held for a myriad of private investors as no RNS's have been made by them. The number of Avacta shares owned by institutional investors is I would suspect less than 25%.

I think there is far more potential in a JV with all our costs covered than a licensing deal in respect of this stem cell therapy developments.

I don't see Avacta selling stake any time soon. Their stake reduces on each round of funding but as we saw earlier in year they get an uplift in stake on reaching certain milestones